These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27723619)

  • 21. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects].
    Rossowska J; Pajtasz-Piasecka E
    Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
    Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
    J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell-based cancer immunotherapies.
    Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
    Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of dendritic cells for cancer vaccination.
    Esche C; Shurin MR; Lotze MT
    Curr Opin Mol Ther; 1999 Feb; 1(1):72-81. PubMed ID: 11249687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loading DCs with Ag.
    Vari F; Hart DN
    Cytotherapy; 2004; 6(2):111-21. PubMed ID: 15203987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
    Rolinski J; Hus I
    J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell based tumor vaccines.
    Nouri-Shirazi M; Banchereau J; Fay J; Palucka K
    Immunol Lett; 2000 Sep; 74(1):5-10. PubMed ID: 10996622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
    Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
    J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
    Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
    J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cell-based immunotherapy.
    Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
    Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cells for specific cancer immunotherapy.
    Meidenbauer N; Andreesen R; Mackensen A
    Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
    Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
    Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
    Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
    Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM
    Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic Cell-Based Cancer Vaccines.
    Santos PM; Butterfield LH
    J Immunol; 2018 Jan; 200(2):443-449. PubMed ID: 29311386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Specialized dendritic cells in cross-presentation of exogenous antigens to cytotoxic T lymphocytes].
    Alfaro C; Oñate C; Rodríguez A; Pérez-Gracia JL; Fernández de Sanmamed M; Melero I
    An Sist Sanit Navar; 2013; 36(3):519-37. PubMed ID: 24406364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.